123 related articles for article (PubMed ID: 14758674)
1. Novel cancer therapies: targeting the molecules.
Gray ML; Khan S; Zimmerman R
JAAPA; 2003 Oct; 16(10):24-7, 31-2. PubMed ID: 14758674
[TBL] [Abstract][Full Text] [Related]
2. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
3. [Target molecules of molecular target therapy of cancer].
Uehara Y
Nihon Rinsho; 2004 Jul; 62(7):1206-8. PubMed ID: 15283134
[No Abstract] [Full Text] [Related]
4. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma.
Dillman RO
J Clin Oncol; 2002 Aug; 20(16):3545-57. PubMed ID: 12177115
[No Abstract] [Full Text] [Related]
5. [New anticancer molecules: drugs for tomorrow?].
Lavelle F
Bull Cancer; 1999 Jan; 86(1):91-5. PubMed ID: 10029711
[No Abstract] [Full Text] [Related]
6. NICE announces guidelines for use of rituximab.
Mayor S
BMJ; 2003 Oct; 327(7418):766. PubMed ID: 14525854
[No Abstract] [Full Text] [Related]
7. New oncology strategy: molecular targeting of cancer cells.
Capriotti T
Medsurg Nurs; 2004 Jun; 13(3):191-5. PubMed ID: 15219169
[No Abstract] [Full Text] [Related]
8. [Clinical observation of Rituximab in a CD20+B non-Hodgkin's lymphoma].
Hao LC; Zhang LZ
Zhonghua Er Ke Za Zhi; 2003 Aug; 41(8):627. PubMed ID: 14744396
[No Abstract] [Full Text] [Related]
9. Rituximab immunotherapy.
Schilder R
Cancer Biother Radiopharm; 1999 Aug; 14(4):237-40. PubMed ID: 10850309
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
11. Engineered antibodies act as targeted therapies in cancer treatment.
Mohindru M; Verma A
Indian J Pediatr; 2005 Nov; 72(11):943-7. PubMed ID: 16391449
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies as therapeutic agents for cancer.
Harris M
Lancet Oncol; 2004 May; 5(5):292-302. PubMed ID: 15120666
[TBL] [Abstract][Full Text] [Related]
13. [Advances in medical oncology].
Shi YK
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):305-10. PubMed ID: 16900620
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy?
Bell IM
J Med Chem; 2004 Apr; 47(8):1869-78. PubMed ID: 15055985
[No Abstract] [Full Text] [Related]
15. Targeted therapies in breast cancer: challenging questions from oncology nurses.
Becze E
ONS Connect; 2007; 22(8 Suppl):31-2. PubMed ID: 17824554
[No Abstract] [Full Text] [Related]
16. [Monoclonal antibodies in the treatment of malignant lymphoma].
Niu Y; Shi YK
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):435-41. PubMed ID: 16900652
[TBL] [Abstract][Full Text] [Related]
17. [Resistance to rituximab and CD20 mutation].
Terui Y; Hatake K
Nihon Rinsho; 2007 Jan; 65 Suppl 1():416-23. PubMed ID: 17474440
[No Abstract] [Full Text] [Related]
18. Empowering targeted therapy: lessons from rituximab.
Olszewski AJ; Grossbard ML
Sci STKE; 2004 Jul; 2004(241):pe30. PubMed ID: 15252219
[TBL] [Abstract][Full Text] [Related]
19. Rituximab for early-stage diffuse large-B-cell lymphoma.
Friedberg JW
Lancet Oncol; 2006 May; 7(5):357-9. PubMed ID: 16648037
[No Abstract] [Full Text] [Related]
20. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
